Drug/Small Molecule:
rosuvastatin

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB annotates drug labels containing pharmacogenetic information approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency, Japan (PMDA). PharmGKB annotations provide a brief summary of the PGx in the label, an excerpt from the label and a downloadable highlighted label PDF file. A list of genes and phenotypes found within the label is mapped to label section headers and listed at the end of each annotation. PharmGKB also attempts to interpret the level of action implied in each label with the "PGx Level" tag.

Sources:

  • FDA Information is gathered from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" and from FDA-approved labels brought to our attention. Please note that drugs may be removed from or added to the FDA's Table without our knowledge. We periodically check the Table for changes and update PharmGKB accordingly. Drugs listed on the Table to our knowledge are tagged with the Biomarker icon. A drug label that has been removed from the Table will not have the Biomarker icon but will continue to have an annotation on PharmGKB stating the label has been removed from the FDA's Table. We acquire label PDF files from DailyMed.
  • EMA European Public Assessment Reports (EPARs) that contain PGx information were identified from [Article:24433361] and also by searching for drugs for which we have PGx-containing FDA drug labels.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA, PMDA or other Medicine Agencies around the world - please contact feedback.


last updated 01/14/2014

FDA Label for rosuvastatin and LDLR

Informative PGx

Summary

Although the rosuvastatin (CRESTOR) drug label does not specifically mention genetic testing, one of the indications listed is for the treatment of homozygous or heterozygous familial hypercholesterolemia, a genetically determined condition often caused by mutations in the low density lipoprotein receptor gene (LDLR). These mutations lead to reduced LDL receptor activity.

Annotation

Excerpt from the rosuvastatin (CRESTOR) drug label:

CRESTOR is an HMG Co-A reductase inhibitor indicated for...patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C and ApoB...pediatric patients 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total-C, LDL-C and ApoB after failing an adequate trial of diet therapy.

In in vivo and in vitro studies, rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL. Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the rosuvastatin drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Cardiovascular Diseases
    • Indications & usage section
    • source: PHONT
  • Hypercholesterolemia
    • Indications & usage section
    • source: PHONT
  • Hyperlipidemias
    • Indications & usage section
    • source: PHONT
  • Ischemic Attack, Transient
    • Warnings section, Adverse reactions section
    • source: PHONT
  • Muscular Diseases
    • Warnings section, Adverse reactions section
    • source: PHONT
  • Myocardial Infarction
    • Indications & usage section
    • source: PHONT
  • Myositis
    • Adverse reactions section
    • source: PHONT
  • Rhabdomyolysis
    • Warnings section, Adverse reactions section
    • source: PHONT
  • Stroke
    • Indications & usage section
    • source: PHONT
  • ABCG2
    • Clinical pharmacology section, metabolism/PK
    • source: FDA Label
  • CYP2C9
    • Clinical pharmacology section, metabolism/PK
    • source: FDA Label
  • CYP3A4
    • Clinical pharmacology section, metabolism/PK
    • source: FDA Label
  • LDLR
    • Indications & usage section, Dosage & administration section, Clinical pharmacology section, Clinical studies section, other
    • source: FDA Label
  • SLCO1B1
    • Clinical pharmacology section, metabolism/PK
    • source: FDA Label

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all rosuvastatin variant annotations

Gene ? Variant?
(142)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA APOE E2 N/A N/A N/A
No VIP available CA No VIP available APOE E3 N/A N/A N/A
No VIP available CA No VIP available APOE E4 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *3 N/A N/A N/A
No VIP available CA VA SLCO1B1 *1A N/A N/A N/A
No VIP available CA VA SLCO1B1 *1B N/A N/A N/A
No VIP available CA VA SLCO1B1 *5 N/A N/A N/A
No VIP available CA VA SLCO1B1 *9 N/A N/A N/A
No VIP available CA VA SLCO1B1 *15 N/A N/A N/A
No VIP available CA VA SLCO1B1 *18 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1169288 11993180A>C, 121416650A>C, 5102A>C, 79A>C, HNF1A:Ile27Leu, Ile27Leu
A > C
Missense
Ile27Leu
No VIP available No Clinical Annotations available VA
rs1205 *1082G>A, 11170875C>T, 159682233C>T, 7147G>A
C > T
3' UTR
No VIP available No Clinical Annotations available VA
rs17238540 2298+117T>G, 2457+117T>G, 25249857T>G, 27506T>G, 74655498T>G, HMGCR:SNP 29
T > G
Intronic
No VIP available No Clinical Annotations available VA
rs1736557 171080080G>A, 22568722G>A, 25063G>A, 769G>A, Val257Met
G > A
Missense
Val257Met
No VIP available CA VA
rs2231142 13600044G>T, 32689C>A, 421C>A, 89052323G>T, ABCG2: Q141K, ABCG2:421C>A, ABCG2:Q141K, ABCG2:c.421C>A, Gln141Lys, rs2231142
G > T
Missense
Gln141Lys
rs2306283 14089862A>G, 21329738A>G, 388A>G, 50611A>G, Asn130Asp, SLCO1B1*1B
A > G
Missense
Asn130Asp
No VIP available No Clinical Annotations available VA
rs2808630 11169510C>T, 159680868C>T, 8512G>A
C > T
Not Available
VIP No Clinical Annotations available No Variant Annotations available
rs4149015 -910G>A, 14043446G>A, 21283322G>A, 4195G>A, SLCO1B1:11187G>A, SLCO1B1:G-11187A
G > A
5' Flanking
rs4149056 14091673T>C, 21331549T>C, 521T>C, 52422T>C, SLCO1B1*5, Val174Ala
T > C
Missense
Val174Ala
No VIP available CA VA
rs4149081 14138145G>A, 1865+248G>A, 21378021G>A, 98894G>A, OATP1B1: intronic A/G
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs4363657 14128846T>C, 1498-1331T>C, 21368722T>C, 89595T>C
T > C
Intronic
No VIP available CA VA
rs4693075 18900C>G, 779-1022C>G, 84192168G>C, 8739889G>C
G > C
Intronic
No VIP available CA No Variant Annotations available
rs6535454 20037T>C, 84191031A>G, 8738752A>G, 894T>C, Asp298=
A > G
Synonymous
Asp298Asp
No VIP available No Clinical Annotations available VA
rs776746 12083G>A, 219-237G>A, 321-1G>A, 37303382C>T, 581-237G>A, 689-1G>A, 99270539C>T, CYP3A5*1, CYP3A5*3, CYP3A5*3C, CYP3A5:6986A>G, g.6986A>G, intron 3 splicing defect, rs776746 A>G
C > T
Acceptor
No VIP available No Clinical Annotations available VA
rs9806699 16530949G>A, 45740392G>A
G > A
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • ZD-4522
  • rosuvastatin calcium
Trade Names
  • Astende
  • Cirantan
  • Cresadex
  • Crestor
  • Provisacor
  • Razel
  • Rosedex
  • Rosimol
  • Rosumed
  • Rosustatin
  • Rosuvas
  • Rosuvast
  • Rosvel
  • Rovartal
  • Simestat
  • Sinlip
  • Visacor
  • Vivacor
Brand Mixture Names

PharmGKB Accession Id:
PA134308647

Description

Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Source: Drug Bank

Indication

Used as an adjunct to dietary therapy to treat primary hypercholesterolemia (heterozygous familial and nonfamilial), mixed dyslipidemia and hypertriglyceridemia. Also indicated for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other such therapies are not available.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Rosuvastatin is a competitive inhibitor of HMG-CoA reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis. Rosuvastatin acts primarily in the liver. Decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. Rosuvastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL). The overall effect is a decrease in plasma LDL and VLDL.
In vitro and in vivo animal studies also demonstrate that rosuvastatin exerts vasculoprotective effects independent of its lipid-lowering properties. Rosuvastatin exerts an anti-inflammatory effect on rat mesenteric microvascular endothelium by attenuating leukocyte rolling, adherence and transmigration (PMID: 11375257). The drug also modulates nitric oxide synthase (NOS) expression and reduces ischemic-reperfusion injuries in rat hearts (PMID: 15914111). Rosuvastatin increases the bioavailability of nitric oxide (PMID: 11375257, 12031849, 15914111) by upregulating NOS (PMID: 12354446) and by increasing the stability of NOS through post-transcriptional polyadenylation (PMID: 17916773). It is unclear as to how rosuvastatin brings about these effects though they may be due to decreased concentrations of mevalonic acid.

Source: Drug Bank

Pharmacology

Rosuvastatin is a synthetic, enantiomerically pure antilipemic agent. It is used to lower total cholesterol, low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), non-high density lipoprotein-cholesterol (non-HDL-C), and trigleride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, rosuvastatin reduces the risk of cardiovascular morbidity and mortality.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Not extensively metabolized. Only ~10% is excreted as metabolite. Cytochrome P450 (CYP) 2C9 is primarily responsible for the formation of rosuvastatin's major metabolite, N-desmethylrosuvastatin. N-desmethylrosuvastatin has approximately 50% of the pharmacological activity of its parent compound in vitro. Rosuvastatin accounts for greater than 87% of the pharmacologic action. Inhibitors of CYP2C9 increase the AUC by less than 2-fold. This interaction does not appear to be clinically significant.

Source: Drug Bank

Protein Binding

90% bound to plasma proteins (mostly albumin)

Source: Drug Bank

Absorption

Bioavailability is approximately 20%

Source: Drug Bank

Half-Life

19 hours

Source: Drug Bank

Toxicity

Generally well-tolerated. Side effects may include myalgia, constipation, asthenia, abdominal pain, and nausea. Other possible side effects include myotoxicity (myopathy, myositis, rhabdomyolysis) and hepatotoxicity. To avoid toxicity in Asian patients, lower doses should be considered. Pharmacokinetic studies show an approximately two-fold increase in peak plasma concentration and AUC in Asian patients (Filipino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian descent) compared to Caucasians patients.

Source: Drug Bank

Route of Elimination

Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%).

Source: Drug Bank

Volume of Distribution

  • 134 L

Source: Drug Bank

Chemical Properties

Chemical Formula

C22H28FN3O6S

Source: Drug Bank

Isomeric SMILES

CC(C)C1=NC(=NC(=C1/C=C/[C@@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C

Source: Drug Bank

CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O

Source: Drug Bank

Canonical SMILES

CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H]

Source: Drug Bank

Average Molecular Weight

481.538

Source: Drug Bank

Monoisotopic Molecular Weight

481.168284538

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Rosuvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ABCG2 (source: Drug Bank)
HMGCR (source: Drug Bank)
NOS3 (source: Drug Bank)

Drug Interactions

Drug Description
rosuvastatin Increased risk of rhabdomyolysis with this combination (source: Drug Bank)
rosuvastatin Increased risk of rhabdomyolysis with this combination (source: Drug Bank)
rosuvastatin Increases the effect and toxicity of rosuvastatin (source: Drug Bank)
rosuvastatin Increases the effect and toxicity of rosuvastatin (source: Drug Bank)
rosuvastatin Rosuvastatin possibly increases the effect of the fibrate (source: Drug Bank)
rosuvastatin Rosuvastatin may increase the effect of fenofibrate. (source: Drug Bank)
rosuvastatin Rosuvastatin possibly increases the effect of the fibrate (source: Drug Bank)
rosuvastatin Rosuvastatin may increase the effect of gemfibrozil. (source: Drug Bank)
rosuvastatin The antiacid decreases the absorption of rosuvastatin (source: Drug Bank)
rosuvastatin The antiacid decreases the absorption of rosuvastatin (source: Drug Bank)
rosuvastatin Concomitant therapy of Rosuvastatin and Tipranavir/Ritonavir may increase Rosuvastatin and Tipranavir concentrations. Consider alternate therapy. (source: Drug Bank)

Curated Information ?

Publications related to rosuvastatin: 41

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial. Journal of atherosclerosis and thrombosis. 2014. Suh Jung-Won, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circulation. Cardiovascular genetics. 2013. DeGorter Marianne K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof of Concept Study Using the Clinical Practice Research Datalink (CPRD). Clinical pharmacology and therapeutics. 2013. Carr Daniel F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013. Mangravite Lara M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013. Lee Hon-Kit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
International transporter consortium commentary on clinically important transporter polymorphisms. Clinical pharmacology and therapeutics. 2013. Giacomini K M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. American heart journal. 2013. Danik Jacqueline S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenetics and genomics. 2012. Hu Miao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. 2011. Becquemont Laurent, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily). The American journal of cardiology. 2010. Hu Miao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenetics and genomics. 2010. Hu Miao, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis. 2010. Puccetti Luca, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression of the hepatic Niemann-Pick C1 like 1 protein gene is sensitive to rosuvastatin treatment of primary human hepatocytes. Pharmacogenetics and genomics. 2010. Brulhart-Meynet Marie-Claude, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study. Circulation. Cardiovascular genetics. 2010. Bailey Kristian M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin. Clinical pharmacology and therapeutics. 2010. Tomlinson B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics. 2010. Yee Sook Wah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors. Clinical pharmacology and therapeutics. 2010. Ichimaru K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics. 2010. Chien Kuo-Liong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter pharmacogenetics and statin toxicity. Clinical pharmacology and therapeutics. 2010. Niemi M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of statin therapy: when the body aches, the mind will follow. Journal of the American College of Cardiology. 2009. Rossi Joseph S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009. Willrich Maria Alice Vieira, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clinical pharmacology and therapeutics. 2009. Keskitalo J E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clinical pharmacology and therapeutics. 2009. Zhang Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenetics and genomics. 2008. Donnelly Louise A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in drug transporters in ethnic populations. Clinical pharmacology and therapeutics. 2008. Cropp C D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Hagenbuch B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clinical pharmacology and therapeutics. 2008. Choi J H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenetics and genomics. 2008. Pasanen Marja K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine. 2008. Ridker Paul M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clinical pharmacology and therapeutics. 2007. Pasanen M K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacological research : the official journal of the Italian Pharmacological Society. 2007. Zuccaro Piergiorgio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rosuvastatin in older patients with systolic heart failure. The New England journal of medicine. 2007. Kjekshus John, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic determinants of statin intolerance. Lipids in health and disease. 2007. Oh Jisun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle & nerve. 2006. Vladutiu Georgirene D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clinica chimica acta; international journal of clinical chemistry. 2006. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical pharmacology and therapeutics. 2006. Neuvonen Pertti J, et al. PubMed
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006. Ho Richard H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clinical pharmacology and therapeutics. 2005. Lee Edmund, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain research. 2002. Laufs Ulrich, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0310-0755-90
DrugBank:
DB01098
PDB:
FBI
ChEBI:
38545
KEGG Drug:
D01915
PubChem Compound:
6439133
PubChem Substance:
706341
Drugs Product Database (DPD):
2247163
BindingDB:
50215703
HET:
FBI
Therapeutic Targets Database:
DAP000555
FDA Drug Label at DailyMed:
bb0f3b5e-4bc6-41c9-66b9-6257e2513512

Clinical Trials

These are trials that mention rosuvastatin and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.